Semaglutide : Primarily focuses on the GLP-1 pathway, helping with appetite regulation and weight loss but lacking the additional benefits that GIP receptor activation provides
More studies, with larger sample sizes and longer follow-up periods, are needed to assess the cardiovascular outcomes of semaglutide. Obesity is a major risk factor for the development of abnormal blood fat levels, type-2 diabetes, high blood pressure, and sleep apnea
In a small study from 2006, more than 50% of people lost at least 10% of their body weight after 14 weeks of phentermine treatment
Sharma N, Chaudhary A, Sharma N (2025) Plant Nutrient Requirements and Nutrient Homeostasis in Plants
Its also common to continue having cravings early in treatment
Our team understands the challenges scientists face, including precision, reproducibility, and time-sensitive experiments